Tipifarnib
- Generic Name
- Tipifarnib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4O
- CAS Number
- 192185-72-1
- Unique Ingredient Identifier
- MAT637500A
- Background
Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
- Indication
Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 98
- Registration Number
- NCT06540963
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT05693090
- Locations
- 🇺🇸
The Valley Hospital, Ridgewood, New Jersey, United States
🇺🇸Providence Medical Group, Santa Rosa, California, United States
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04997902
- Locations
- 🇺🇸
University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center), Baltimore, Maryland, United States
🇺🇸Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center), Baltimore, Maryland, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04865159
- Locations
- 🇺🇸
NEXT Oncology, San Antonio, Texas, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
Expanded Access to Tipifarnib
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kura Oncology, Inc.
- Registration Number
- NCT04809233
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT04284774
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 296
- Registration Number
- NCT03719690
- Locations
- 🇺🇸
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
- First Posted Date
- 2018-04-12
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Spanish Lung Cancer Group
- Target Recruit Count
- 9
- Registration Number
- NCT03496766
- Locations
- 🇪🇸
Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, A Coruña, Spain
🇪🇸Hospital Virgen de los Lirios, Alcoy, Alicante, Spain
🇪🇸Hospital General Universitario de Elche, Elche, Alicante, Spain
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionOther: Laboratory Biomarker AnalysisProcedure: Bone Marrow Aspiration and BiopsyDrug: Larotrectinib SulfateProcedure: Bone ScanProcedure: Mutation Carrier ScreeningOther: Pharmacological StudyProcedure: Computed TomographyDrug: OlaparibDrug: PalbociclibDrug: Selumetinib SulfateDrug: TipifarnibDrug: ErdafitinibDrug: TazemetostatDrug: SamotolisibDrug: EnsartinibDrug: VemurafenibDrug: UlixertinibProcedure: Magnetic Resonance ImagingDrug: SelpercatinibProcedure: Positron Emission TomographyProcedure: Radionuclide ImagingProcedure: X-Ray Imaging
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2316
- Registration Number
- NCT03155620
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸East Carolina University, Greenville, North Carolina, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02807272
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.